Scientists isolated a new class of antibiotics from the soil bacterial species Eleftheria terra using a new form of technology called an iChip. This discovery opens the doors to many other breakthroughs in healthcare technology. It is highly effective, therefore it is extremely proficient in destroying all resistant strains of bacteria. Furthermore, it can provide an alternative avenue of antibiotics for individuals who are allergic or unable to take the current medication.
Furthermore, scientists tested Teixobactin has against pathogenic strands of Staphylococcus aureus, MRSA, Streptococcus pneumonia, Mycobacterium tuberculosis, Clostridium difficile, and Bacillus anthracis. They accomplished this by giving each of the representative strains of bacteria a single dose of the Teixobactin. These experiments concluded that no resistant bacteria remained in every species tested. Additionally, more studies have shown that it also decreased the pathogenic cell density in septic MRSA infections and pneumococcal pneumonia.
How Does it Work?
The chemical antibiotic, termed Teixobactin, inhibits bacterial wall formation by inhibiting the synthesis of its main component, peptidoglycan. Teixobactin does this by binding to specific molecules called lipid I and lipid II. These molecules serve as precursors to peptidoglycan and teichoic acid respectively. It is therefore primarily active against Gram-positive strains of bacteria and is projected to not affect Gram-negative strains because of their different exterior anatomy.
In addition, antibiotics have been a significant concern in the medical community for years. The increased frequency of antibiotic use has led to the development of resistant bacteria strains and diminished the efficacy of the antibiotic. Therefore, researchers are always in search of new antibiotic agents, such as Teixobactin, that could potentially be effective against pathogenic bacterial strains without creating more resistant strains. They addressed this by isolating the antibacterial chemical, Teixobactin, and placing it in growths of Gram-negative and Gram-positive bacteria species. It proved ineffective against the Gram-negative strains. However, the antimicrobial proved effective against all Gram-positive strains. Moreover, further testing found this approach to be valid with conclusive data that showed that diminished resistant strains in any of the original bacterial cultures.
Furthermore, Teixobactin introduces a new possibility of antibiotic medication into the healthcare system. Penicillin is the most commonly used antibiotic today. The frequent use of it not only creates resistant strains, but it also inhibits those who are allergic to it because they are unable to take advantage of the antibiotic when they suffer from an infection from common pathogenic bacterial species. The introduction of a new antimicrobial would allow people who are allergic to Penicillin to have alternative medicines that are effective against common pathogens.
For more information, visit our website https://dynagrace.com/.
Resources: https://www.nature.com/articles/nature14098/figures/11, https://academic.oup.com/jac/article/70/10/2679/830198, https://newatlas.com/new-novel-antibiotic-success-animal-testing/53943/, https://www.ncbi.nlm.nih.gov/pubmed/28770988, https://www.sciencedaily.com/releases/2017/11/171106112241.htm, https://phys.org/news/2017-06-scientists-closer-defeating-superbugs-teixobactin.html, https://aac.asm.org/content/60/11/6510
Picture Resources: Featured Image: https://pixabay.com/en/addiction-antibiotic-capsule-care-71574/, https://www.mediawiki.org/wiki/File:Gram_Stain_Anthrax.jpg, https://pixabay.com/en/thermometer-headache-pain-pills-1539191/, https://pixabay.com/en/antibiotics-asia-baby-the-bacteria-1782433/